RBOT.WS تصريحات هيئة الأوراق المالية والبورصات - Vicarious Surgical Inc. - Equity Warrant- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

CIK

1812173

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vicarious Surgical Inc. - Equity Warrant

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

August 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 VICARIOUS SURGICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission
August 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICARIOUS
August 12, 2025	EX-99.1	Vicarious Surgical Reports Second Quarter 2025 Financial Results Exhibit 99.1 Vicarious Surgical Reports Second Quarter 2025 Financial Results WALTHAM, Mass.- (BUSINESS WIRE) – August 12, 2025 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the second quarter ended June 30, 2025. M
July 31, 2025	EX-10.1	Executive Employment Agreement, dated as of July 30, 2025, between Vicarious Surgical Inc. and Stephen From Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), is made and entered into this 30th day of July, 2025 (the “Execution Date”), and is by and between Vicarious Surgical Inc. (“Company”), and Stephen From (“Executive”). WHEREAS, Company wishes to employ Executive to serve as its Chief Executive Officer; WHEREAS, Executive represents that Executive pos
July 31, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission F
July 31, 2025	EX-99.1	Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer Adam Sachs, Co-Founder, to Remain on as President Exhibit 99.1 Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer Adam Sachs, Co-Founder, to Remain on as President WALTHAM, Mass. - (BUSINESS WIRE) – July 31, 2025 - Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic
July 11, 2025	EX-16.1	Letter from Deloitte & Touche LLP dated July 11, 2025 Exhibit 16.1 Deloitte & Touche LLP 115 Federal Street Boston, MA 02110 USA Tel: +1 617 437 2000 Fax: +1 617 437 2111 www.deloitte.com July 11, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Vicarious Surgical Inc.’s Form 8-K dated July 11, 2025, and we agree with the statements made in the second, third and fourth
July 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 VICARIOUS SURGICAL I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission Fi
July 2, 2025	S-8	As filed with the Securities and Exchange Commission on July 2, 2025 As filed with the Securities and Exchange Commission on July 2, 2025 Registration No.
July 2, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Vicarious Surgical Inc.
June 30, 2025	EX-10.1	Vicarious Surgical Inc. 2021 Equity Incentive Plan, as amended, and forms of agreement thereunder Exhibit 10.1 VICARIOUS SURGICAL INC. 2021 EQUITY INCENTIVE PLAN, AS AMENDED (As approved by the stockholders on June 27, 2025) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Vicarious Surgical Inc. 2021 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated po
June 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 VICARIOUS SURGICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission F
June 30, 2025	EX-99.1	Vicarious Surgical Announces Election of New Directors Exhibit 99.1 Vicarious Surgical Announces Election of New Directors WALTHAM, Mass. - (BUSINESS WIRE) - Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the election of Fuad Ahmad and Joseph Doherty to the Vicarious Surgical Board of Directors at the Company’s 2025 A
June 30, 2025	EX-10.2	Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.2 Vicarious Surgical Inc. Amended and Restated Non-Employee Director Compensation Policy Non-employee members of the board of directors (the “Board”) of Vicarious Surgical Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation described in this Policy shall be paid o
May 13, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission Fi
May 13, 2025	EX-99.1	Vicarious Surgical Reports First Quarter 2025 Financial Results Exhibit 99.1 Vicarious Surgical Reports First Quarter 2025 Financial Results WALTHAM, Mass.- (BUSINESS WIRE) – May 12, 2025 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2025. Manag
May 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICARIOUS
April 29, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as
April 29, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1
April 11, 2025	EX-99.1	Vicarious Surgical Receives Continued Listing Standard Notice from the NYSE Exhibit 99.1 Vicarious Surgical Receives Continued Listing Standard Notice from the NYSE WALTHAM, Mass.- (BUSINESS WIRE) – April 11, 2025 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on April 10, 2025, the Company received written
April 11, 2025	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission
March 24, 2025	EX-99.1	Vicarious Surgical Announces President Transition to Board Member Role Exhibit 99.1 Vicarious Surgical Announces President Transition to Board Member Role WALTHAM, Mass.- (BUSINESS WIRE) – March 24, 2025 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that Company President, Randy Clark, will transition to Bo
March 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 VICARIOUS SURGICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission
March 17, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission
March 17, 2025	EX-19	Vicarious Surgical Inc. Insider Trading Policy Exhibit 19 VICARIOUS SURGICAL INC. INSIDER TRADING POLICY (Effective September 17, 2021, revised January 8, 2025) TABLE OF CONTENTS Page I. The Need for an Insider Trading Policy 1 II. What is Material Non-Public Information? 1 III. The Consequences of Insider Trading 3 IV. Our Policy 4 General Prohibition on Trading 4 Transactions by Family Members, Others in Your Household and Entities You Contr
March 17, 2025	EX-99.1	Vicarious Surgical Reports Fourth Quarter and Full Year 2024 Financial Results Version 1.0 System Integration Complete; Progressing Towards First Clinical Use Achieved 2024 Cash Burn Guidance; Sets 2025 Cash Burn Guidance of $50 Million Exhibit 99.1 Vicarious Surgical Reports Fourth Quarter and Full Year 2024 Financial Results Version 1.0 System Integration Complete; Progressing Towards First Clinical Use Achieved 2024 Cash Burn Guidance; Sets 2025 Cash Burn Guidance of $50 Million WALTHAM, Mass.- (BUSINESS WIRE) – March 17, 2025 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-gener
March 17, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICARIOUS SURGICAL INC. (
March 17, 2025	EX-4.1	Description of Securities Exhibit 4.1 DESCRIPTION OF The registrant’s SECURITIES The following summary of the material terms of the capital stock of Vicarious Surgical (formerly D8 Holdings Corp.) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Certificate of Incorporation (the “Charter”), our Amended and Restated Bylaws (the “Bylaws”) and the
March 17, 2025	EX-97	Vicarious Surgical Inc. Clawback Policy Exhibit 97 Vicarious Surgical Inc. CLAWBACK POLICY Adopted July 18, 2023 I. Introduction The Board of Directors (the “Board”) of Vicarious Surgical Inc (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosoph
March 17, 2025	EX-10.5	Consulting Agreement, dated as of January 17, 2025, by and between Vicarious Surgical Inc. and William Kelly. Exhibit 10.5 Vicarious Surgical Inc. Consulting Agreement This Consulting Agreement (the “Agreement”), made as of the 2nd day of January, 2025, is entered into by Vicarious Surgical Inc., a Delaware corporation (the “Company”), and William Kelly, an individual residing at 552 Victory Road, Unit 531, Quincy, MA 02171 (the “Consultant”). WHEREAS, the Company and the Consultant desire to establish th
March 13, 2025	EX-99.1	Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Exhibit 99.1 Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development WALTHAM, Mass.- (BUSINESS WIRE) – March 13, 2025 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seek
March 13, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission
March 13, 2025	EX-10.1	Offer Letter dated March 3, 2025, by and between the Company and Sarah Romano Exhibit 10.1 Vicarious Surgical Inc. 78 FOURTH AVE WALTHAM, MA 02451 March 3, 2025 BY EMAIL Sarah Romano [email protected] Re: Executive Offer of Employment Dear Sarah: It gives me great pleasure to offer you employment with Vicarious Surgical Inc., a Delaware corporation (the “Company”). The purpose of this letter is to summarize the terms of your employment with the Company should you acc
February 18, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissi
February 18, 2025	EX-99.1	Vicarious Surgical Announces Planned Retirement of Chief Operating Officer Exhibit 99.1 Vicarious Surgical Announces Planned Retirement of Chief Operating Officer WALTHAM, Mass.- (BUSINESS WIRE) – February 18, 2025 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced Chief Operating Officer (COO) John Mazzola will ret
January 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 VICARIOUS SURGIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissio
December 6, 2024	EX-99.1	Vicarious Surgical Announces Departure of Chief Financial Officer Exhibit 99.1 Vicarious Surgical Announces Departure of Chief Financial Officer WALTHAM, Mass.- (BUSINESS WIRE) – December 6, 2024 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the pending departure of William Kelly, its Chief Financial O
December 6, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissio
November 12, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissi
November 12, 2024	EX-99.1	Vicarious Surgical Reports Third Quarter 2024 Financial Results Exhibit 99.1 Vicarious Surgical Reports Third Quarter 2024 Financial Results WALTHAM, Mass.- (BUSINESS WIRE) – November 12, 2024 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter ended September 30, 2024. Ma
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICAR
August 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICARIOUS
August 13, 2024	EX-3.1	Certificate of Incorporation of Vicarious Surgical Inc., as amended Exhibit 3.1 CERTIFICATE OF INCORPORATION OF VICARIOUS SURGICAL INC. Pursuant to the General Corporation Law of the State of Delaware ARTICLE 1. NAME The name of the corporation is Vicarious Surgical Inc. ARTICLE 2. REGISTERED OFFICE AND AGENT The address of its registered office in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, DE 19801. The name of its registered a
August 12, 2024	EX-99.1	Vicarious Surgical Reports Second Quarter 2024 Financial Results Exhibit 99.1 Vicarious Surgical Reports Second Quarter 2024 Financial Results WALTHAM, Mass.- (BUSINESS WIRE) – August 12, 2024 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter ended June 30, 2024. Manageme
August 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 VICARIOUS SURGICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission
June 27, 2024	EX-4.4	Specimen Class A Common Stock Certificate. Exhibit 4.4
June 27, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Vicarious Surgical Inc.
June 27, 2024	EX-99.1	Vicarious Surgical Inc. 2021 Equity Incentive Plan, as amended, and forms of agreement thereunder. Exhibit 99.1 VICARIOUS SURGICAL INC. 2021 EQUITY INCENTIVE PLAN, AS AMENDED (As approved by the stockholders on June 10, 2024) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Vicarious Surgical Inc. 2021 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated po
June 27, 2024	S-8	As filed with the Securities and Exchange Commission on June 27, 2024 As filed with the Securities and Exchange Commission on June 27, 2024 Registration No.
June 14, 2024	EX-3.1	Certificate of Amendment to the Certificate of Incorporation of the Registrant, as filed with the Secretary of State of the State of Delaware on June 12, 2024 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF VICARIOUS SURGICAL INC. Vicarious Surgical Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware as set forth in Title 8 of the Delaware Code (the “DGCL”), hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends th
June 14, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission F
June 10, 2024	EX-99.1	Vicarious Surgical Announces Reverse Stock Split Exhibit 99.1 Vicarious Surgical Announces Reverse Stock Split WALTHAM, Mass. - (BUSINESS WIRE) - Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives through the transformation of surgical robotics, today announced it will effect a 1-for-30 reverse stock split of the Company’s issued and outsta
June 10, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission F
May 13, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
April 29, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission
April 29, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICARIOUS
April 29, 2024	EX-99.1	Vicarious Surgical Reports First Quarter 2024 Financial Results Exhibit 99.1 Vicarious Surgical Reports First Quarter 2024 Financial Results WALTHAM, Mass.- (BUSINESS WIRE) – April 29, 2024 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives through the transformation of surgical robotics, today announced financial results for the quarter ended March 31,
April 23, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A 1 ny20021316x3defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl
April 23, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
April 12, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
March 4, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissi
March 4, 2024	EX-99.1	Vicarious Surgical Reports Fourth Quarter and Full Year 2023 Financial Results Version 1.0 Surgical System On Track for Cadaveric Testing in the Spring Achieves Full Year 2023 Cash Burn Objective of $63.4 Million Narrows Full Year 2024 Cash Burn Guid Exhibit 99.1 Vicarious Surgical Reports Fourth Quarter and Full Year 2023 Financial Results Version 1.0 Surgical System On Track for Cadaveric Testing in the Spring Achieves Full Year 2023 Cash Burn Objective of $63.4 Million Narrows Full Year 2024 Cash Burn Guidance to Approximately $50 Million WALTHAM, Mass.- (BUSINESS WIRE) – March 4, 2024 – Vicarious Surgical Inc. (“Vicarious Surgical” or the
March 4, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39384 VICARIOUS SURGICAL INC. (E
March 4, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission F
March 4, 2024	EX-4.1	Description of Securities Exhibit 4.1 DESCRIPTION OF The registrant’s SECURITIES The following summary of the material terms of the capital stock of Vicarious Surgical (formerly D8 Holdings Corp.) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Certificate of Incorporation (the “Charter”), our Amended and Restated Bylaws (the “Bylaws”) and the
March 4, 2024	EX-10.6	Offer Letter, dated January 18, 2024, by and between Vicarious Surgical Inc. and Randy Clark. Exhibit 10.6 Vicarious Surgical Inc. 78 Fourth Ave Waltham, MA 02451 January 18, 2024 BY EMAIL Randy Clark Re: Offer of Employment Dear Randy: It gives me great pleasure to offer you employment with Vicarious Surgical Inc., a Delaware corporation (the “Company”). The purpose of this letter is to summarize the terms of your employment with the Company should you accept our offer. 1. Position. You w
February 13, 2024	SC 13G/A	RBOT / Vicarious Surgical Inc. / Gates Ventures, Llc - SC 13G/A Passive Investment SC 13G/A 1 tm245599d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vicarious Surgical Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 92561V109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Ch
January 29, 2024	EX-99.1	Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President Exhibit 99.1 Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President WALTHAM, Mass. - (BUSINESS WIRE) - Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that
January 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 VICARIOUS SURGIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissio
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 VICARIOUS SURGI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissi
November 13, 2023	EX-99.2	INVESTOR PRESENTATION NOVEMBER 2023 0 0 \| SUMMA R Y VICARIOUS SURGICAL INVESTOR PRESENTATION NOVEMBER 2023 2 DISCLAIMER This presentation includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the United States Exhibit 99.2 INVESTOR PRESENTATION NOVEMBER 2023 0 0 \| SUMMA R Y VICARIOUS SURGICAL INVESTOR PRESENTATION NOVEMBER 2023 2 DISCLAIMER This presentation includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The company’s actual results may differ from its expectations, estimates, and projectio
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICAR
November 13, 2023	EX-99.1	Vicarious Surgical Reports Third Quarter 2023 Financial Results Exhibit 99.1 Vicarious Surgical Reports Third Quarter 2023 Financial Results WALTHAM, Mass.- (BUSINESS WIRE) – November 13, 2023 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results fo
September 22, 2023	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 Vicarious Surgical Inc. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commiss
September 22, 2023	EX-99.1	Vicarious Surgical Receives Continued Listing Standard Notice From NYSE Exhibit 99.1 Vicarious Surgical Receives Continued Listing Standard Notice From NYSE WALTHAM, Mass.-(BUSINESS WIRE)- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that on September 20, 2023, it rec
August 15, 2023	SC 13G/A	RBOT / Vicarious Surgical Inc - Class A / SUN HUNG KAI & CO LTD - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Vicarious Surgical Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 9256
August 15, 2023	EX-99	Joint Filing Agreement. CUSIP No. 92561V109 Schedule 13G Page 1 of 1 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and acc
August 9, 2023	SC 13D/A	RBOT / Vicarious Surgical Inc - Class A / Khosla Ventures V, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vicarious Surgical Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 92561V109 (CUSIP Number) John Demeter Khosla Ventures 2128 Sand Hill Road Menlo Park, California 94025 (650) 376-8500 (Name
August 9, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. Dated: August 9, 2023 KHOSLA VENTURE
August 4, 2023	EX-1.1	Underwriting Agreement, dated August 2, 2023, by and among the Company and Morgan Stanley & Co. LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein Exhibit 1.1 $45,000,000 OF SHARES OF Vicarious Surgical Inc. Class A common stock, par value $0.0001 per share UNDERWRITING AGREEMENT August 2, 2023 August 2, 2023 Morgan Stanley & Co. LLC Cowen and Company, LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: Vicarious Surgical Inc.,
August 4, 2023	424B5	45,000,000 Shares Vicarious Surgical Inc. Class A Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-267785 Prospectus Supplement (To prospectus dated October 27, 2022) 45,000,000 Shares Vicarious Surgical Inc. Class A Common Stock We are offering 45,000,000 shares of our Class A common stock, par value $0.0001 per share. Our Class A common stock is listed on the New York Stock Exchange under the stock symbol “RBOT.” On August 2, 2023, the las
August 4, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 Vicarious Surgical Inc. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission
August 4, 2023	EX-99.1	Vicarious Surgical Announces Launch of Proposed Public Offering Exhibit 99.1 Vicarious Surgical Announces Launch of Proposed Public Offering WALTHAM, Mass, August 2, 2023 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that it has commenced an underwritten publ
August 4, 2023	EX-99.2	Vicarious Surgical Announces Pricing of Public Offering Exhibit 99.2 Vicarious Surgical Announces Pricing of Public Offering WALTHAM, Mass, August 2, 2023 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the pricing of its underwritten public offering of
August 2, 2023	424B5	Subject to completion, dated August 2, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-267785 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a
July 28, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICARIOUS
July 28, 2023	EX-3.1	Certificate of Incorporation of Vicarious Surgical Inc., as amended Exhibit 3.1 CERTIFICATE OF INCORPORATION OF VICARIOUS SURGICAL INC. Pursuant to the General Corporation Law of the State of Delaware ARTICLE 1. NAME The name of the corporation is Vicarious Surgical Inc. ARTICLE 2. REGISTERED OFFICE AND AGENT The address of its registered office in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, DE 19801. The name of its registered a
July 27, 2023	EX-99.1	INVESTOR PRESENTATION JULY 2023 DISCLAIMER VICARIOUS SURGICAL INVESTOR PRESENTATION JULY 2023 00 \| SUMMARY 2 This presentation includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the United States Private Sec Exhibit 99.1 INVESTOR PRESENTATION JULY 2023 DISCLAIMER VICARIOUS SURGICAL INVESTOR PRESENTATION JULY 2023 00 \| SUMMARY 2 This presentation includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The company’s actual results may differ from its expectations, estimates, and projections and, con
July 27, 2023	EX-99.1	Vicarious Surgical Reports Second Quarter 2023 Financial Results and Announces Clinical Plan and Regulatory Intent Exhibit 99.1 Vicarious Surgical Reports Second Quarter 2023 Financial Results and Announces Clinical Plan and Regulatory Intent WALTHAM, Mass.- (BUSINESS WIRE) – July 27, 2023 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical p
July 27, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission F
July 27, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission F
July 18, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Vicarious Surgical Inc.
July 18, 2023	S-8	As filed with the Securities and Exchange Commission on July 17, 2023 As filed with the Securities and Exchange Commission on July 17, 2023 Registration No.
June 7, 2023	EX-3.1	Certificate of Amendment to the Certificate of Incorporation of the Registrant, as filed with the Secretary of State of the State of Delaware on June 6, 2023 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF VICARIOUS SURGICAL INC. It is hereby certified that: 1. The name of the corporation is Vicarious Surgical Inc. (the “Corporation”): 2. The Certificate of Incorporation of the Corporation is hereby amended by striking out Section (A) of Article 8 in its entirety and by substituting the following in lieu thereof: (A) Limited Lia
June 7, 2023	EX-10.2	Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.2 Vicarious Surgical Inc. Amended and Restated Non-Employee Director Compensation Policy Non-employee members of the board of directors (the “Board”) of Vicarious Surgical Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation described in this Policy shall be paid o
June 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 VICARIOUS SURGICAL I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission Fi
June 7, 2023	EX-10.1	Vicarious Surgical Inc. 2021 Equity Incentive Plan, as amended, and forms of agreement thereunder Exhibit 10.1 VICARIOUS SURGICAL INC. 2021 EQUITY INCENTIVE PLAN, AS AMENDED (As approved by the stockholders on June 1, 2023) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Vicarious Surgical Inc. 2021 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated pow
May 18, 2023	EX-99.1	Vicarious Surgical Announces Promotion of John Mazzola to Chief Operating Officer Exhibit 99.1 Vicarious Surgical Announces Promotion of John Mazzola to Chief Operating Officer WALTHAM, Mass.- (BUSINESS WIRE) – May 18, 2023 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the pro
May 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 VICARIOUS SURGICAL I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission Fi
May 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICARIOUS
May 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission Fil
May 8, 2023	EX-99.1	Vicarious Surgical Reports First Quarter 2023 Financial Results Exhibit 99.1 Vicarious Surgical Reports First Quarter 2023 Financial Results WALTHAM, Mass.- (BUSINESS WIRE) – May 8, 2023 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the
April 25, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
April 14, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
February 15, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39384 VICARIOUS SURGICAL INC. (E
February 14, 2023	EX-99.1	Vicarious Surgical Reports Fourth Quarter and Full Year 2022 Financial Results Meets Full Year 2022 Cash Burn Objective of $67 Million Announces Cost-Reduction Initiatives to Optimize Cash Burn and Extend Cash Runway Provides Full Year 2023 Cash Burn Exhibit 99.1 Vicarious Surgical Reports Fourth Quarter and Full Year 2022 Financial Results Meets Full Year 2022 Cash Burn Objective of $67 Million Announces Cost-Reduction Initiatives to Optimize Cash Burn and Extend Cash Runway Provides Full Year 2023 Cash Burn Guidance of $55-$65 Million WALTHAM, Mass.- (BUSINESS WIRE) – February 13, 2023 – Vicarious Surgical Inc. (“Vicarious Surgical” or the “
February 14, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissi
February 7, 2023	SC 13G/A	RBOT / Vicarious Surgical Inc - Class A / SUN HUNG KAI & CO LTD - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Vicarious Surgical Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 9256
February 7, 2023	EX-99	Joint Filing Agreement CUSIP No. 92561V109 Schedule 13G Page 1 of 1 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and acc
January 23, 2023	EX-99.1	Vicarious Surgical Announces Changes to Board of Directors Victoria Carr-Brendel, Ph.D. Elected to Board of Directors Tech-Focused Venture Capitalist Phil Liang to Resign Exhibit 99.1 Vicarious Surgical Announces Changes to Board of Directors Victoria Carr-Brendel, Ph.D. Elected to Board of Directors Tech-Focused Venture Capitalist Phil Liang to Resign WALTHAM, Mass.-(BUSINESS WIRE)- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today
January 23, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissio
December 28, 2022	SC 13G/A	RBOT / Vicarious Surgical Inc - Class A / Bright Insight Holdings Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vicarious Surgical Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 92561V109 (CUSIP Number) November 16, 2022 Date of Event Which Requires Filing of this Statement Check the appropriate box to design
December 2, 2022	SC 13G/A	RBOT / Vicarious Surgical Inc - Class A / Cadin Ltd. - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vicarious Surgical Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 92561V109 (CUSIP Number) November 3, 2022 Date of Event Which Requires Filing of this Statement Check the appropriate box to designa
November 7, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissio
November 7, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICAR
November 7, 2022	EX-99.1	Vicarious Surgical Reports Third Quarter 2022 Financial Results Exhibit 99.1 Vicarious Surgical Reports Third Quarter 2022 Financial Results WALTHAM, Mass.- (BUSINESS WIRE) ? November 7, 2022 ? Vicarious Surgical Inc. (?Vicarious Surgical? or the ?Company?) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for
October 28, 2022	424B5	Vicarious Surgical Inc. Class A common stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-267785 PROSPECTUS Vicarious Surgical Inc. $100,000,000 Class A common stock We have entered into a Sales Agreement, or sales agreement, with Cowen and Company, LLC, or Cowen, dated October 7, 2022, relating to the sale of shares of our Class A common stock offered by this prospectus. In accordance with the terms of the sales agreement
October 25, 2022	CORRESP	VICARIOUS SURGICAL INC. 78 Fourth Avenue Waltham, Massachusetts 02451 VICARIOUS SURGICAL INC. 78 Fourth Avenue Waltham, Massachusetts 02451 October 25, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jordan Nimitz RE: Vicarious Surgical Inc. Registration Statement on Form S-3 Filed October 7, 2022 File No. 333-267785 Acceleration Request Dear Ms. Nimitz: With respect
October 20, 2022	EX-99.1	Vicarious Surgical Announces Changes to Board of Directors Tech-Focused Venture Capitalists Dror Berman and Samir Kaul to Resign Beverly Huss Elected to Board of Directors Exhibit 99.1 Vicarious Surgical Announces Changes to Board of Directors Tech-Focused Venture Capitalists Dror Berman and Samir Kaul to Resign Beverly Huss Elected to Board of Directors Waltham, Mass., October 20, 2022 ? Vicarious Surgical Inc. (?Vicarious Surgical? or the ?Company?), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, to
October 20, 2022	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissio
October 13, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissio
October 13, 2022	EX-99.1	Vicarious Surgical Announces Upcoming Beta 2 Demonstration Day Exhibit 99.1 Vicarious Surgical Announces Upcoming Beta 2 Demonstration Day Waltham, Mass., October 13, 2022 ? Vicarious Surgical, Inc. (?Vicarious Surgical? or the ?Company?), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced that it will host a Demonstration Day of its Beta 2 surgical robot prototype for investors and
October 11, 2022	424B3	Filed Pursuant to Rule 424(b)(3) Registration No. 333-260281 Filed Pursuant to Rule 424(b)(3) Registration No. 333-260281 PROSPECTUS VICARIOUS SURGICAL INC. Up to 103,781,408 Shares of Class A Common Stock Up to 19,686,297 Shares of Class B Common Stock Up to 10,400,000 Warrants This prospectus relates to the resale from time to time by the Selling Securityholders named in this prospectus (the ?Selling Securityholders?) of up to (i) 10,400,000 Private Place
October 7, 2022	EX-1.2	Sales Agreement, dated as of October 7, 2022, by and between the Registrant and Cowen and Company, LLC Exhibit 1.2 VICARIOUS SURGICAL INC. $100,000,000 COMMON STOCK SALES AGREEMENT October 7, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Vicarious Surgical Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Placement Shares. The Company agrees th
October 7, 2022	EX-4.10	Form of Subordinated Indenture. Exhibit 4.10 VICARIOUS SURGICAL INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313
October 7, 2022	S-3	As filed with the Securities and Exchange Commission on October 7, 2022 As filed with the Securities and Exchange Commission on October 7, 2022 Registration No.
October 7, 2022	EX-4.9	Form of Senior Indenture. Exhibit 4.9 VICARIOUS SURGICAL INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.
October 7, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Vicarious Surgical Inc.
October 3, 2022	POS AM	As filed with the U.S. Securities and Exchange Commission on October 3, 2022 As filed with the U.S. Securities and Exchange Commission on October 3, 2022 Registration No. 333-260281 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vicarious Surgical Inc. (Exact name of registrant as specified in its charter) Delaware 87-2678169 (State or oth
August 8, 2022	424B3	VICARIOUS SURGICAL INC. Up to 122,932,036 Shares of Class A Common Stock Up to 19,789,860 Shares of Class B Common Stock Up to 10,400,000 Warrants PROSPECTUS SUPPLEMENT NO. 3 Filed Pursuant to Rule 424(b)(3) To Prospectus dated April 4, 2022 Registration No. 333-260281 VICARIOUS SURGICAL INC. Up to 122,932,036 Shares of Class A Common Stock Up to 19,789,860 Shares of Class B Common Stock Up to 10,400,000 Warrants This prospectus supplement no. 3 supplements the prospectus dated April 4, 2022, as supplemented from time to time (the ?Prospectu
August 8, 2022	EX-99.1	Vicarious Surgical Reports Second Quarter 2022 Financial Results Exhibit 99.1 Vicarious Surgical Reports Second Quarter 2022 Financial Results WALTHAM, Mass.- (BUSINESS WIRE) ? August 8, 2022 ? Vicarious Surgical Inc. (?Vicarious Surgical? or the ?Company?) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for
August 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission
August 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICARIOUS
July 26, 2022	SC 13G	RBOT / Vicarious Surgical Inc - Class A / Cadin Ltd. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vicarious Surgical Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 92561V109 (CUSIP Number) July 13, 2022 Date of Event Which Requires Filing of this Statement Check the appropriate box to designate t
July 26, 2022	EX-99.1	Joint Filing Agreement. EXHIBIT 99.1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the ?Exchange Act?) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including any amendment, restat
July 25, 2022	EX-99.1	Joint Filing Agreement. EXHIBIT 99.1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the ?Exchange Act?) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including any amendment, restat
July 25, 2022	SC 13G	RBOT / Vicarious Surgical Inc - Class A / Bright Insight Holdings Ltd. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Vicarious Surgical Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 92561V109 (CUSIP Number) July 13, 2022 Date of Event Which Requires Filing of this Statement Check the appropriate box to designate th
July 25, 2022	SC 13G/A	RBOT / Vicarious Surgical Inc - Class A / D8 Sponsor LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vicarious Surgical Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 92561V109 (CUSIP Number) July 13, 2022 Date of Event Which Requires Filing of this Statement Check the appropriate box to designat
June 13, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 ea161450ex-feevicarious.htm FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Vicarious Surgical Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rat
June 13, 2022	S-8	As filed with the Securities and Exchange Commission on June 13, 2022 S-8 1 ea161450-s8vicarious.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on June 13, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vicarious Surgical Inc. (Exact name of registrant as specified in its charter) Delaware 87-2678169 (State or other ju
June 3, 2022	EX-10.1	Vicarious Surgical Inc. 2021 Equity Incentive Plan, as amended, and forms of agreement thereunder. Exhibit 10.1 VICARIOUS SURGICAL INC. 2021 EQUITY INCENTIVE PLAN, AS AMENDED (As approved by the stockholders on June 1, 2022) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Vicarious Surgical Inc. 2021 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated pow
June 3, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission Fi
June 3, 2022	424B3	VICARIOUS SURGICAL INC. Up to 122,932,036 Shares of Class A Common Stock Up to 19,789,860 Shares of Class B Common Stock Up to 10,400,000 Warrants PROSPECTUS SUPPLEMENT NO. 2 Filed Pursuant to Rule 424(b)(3) To Prospectus dated April 4, 2022 Registration No. 333-260281 VICARIOUS SURGICAL INC. Up to 122,932,036 Shares of Class A Common Stock Up to 19,789,860 Shares of Class B Common Stock Up to 10,400,000 Warrants This prospectus supplement no. 2 supplements the prospectus dated April 4, 2022, as supplemented from time to time (the ?Prospectu
May 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICARIOUS
May 9, 2022	EX-10.1	Amended and Restated Nonemployee Director Compensation Policy. Exhibit 10.1 Vicarious Surgical Inc. Amended and Restated Non-Employee Director Compensation Policy Non-employee members of the board of directors (the ?Board?) of Vicarious Surgical Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this ?Policy?). The cash and equity compensation described in this Policy shall be paid o
May 9, 2022	EX-99.1	Vicarious Surgical Reports First Quarter 2022 Financial Results Exhibit 99.1 Vicarious Surgical Reports First Quarter 2022 Financial Results WALTHAM, Mass.- (BUSINESS WIRE) ? May 9, 2022 ? Vicarious Surgical Inc. (?Vicarious Surgical? or the ?Company?) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the
May 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission Fil
May 9, 2022	424B3	VICARIOUS SURGICAL INC. Up to 122,932,036 Shares of Class A Common Stock Up to 19,789,860 Shares of Class B Common Stock Up to 10,400,000 Warrants PROSPECTUS SUPPLEMENT NO. 1 Filed Pursuant to Rule 424(b)(3) To Prospectus dated April 4, 2022 Registration No. 333-260281 VICARIOUS SURGICAL INC. Up to 122,932,036 Shares of Class A Common Stock Up to 19,789,860 Shares of Class B Common Stock Up to 10,400,000 Warrants This prospectus supplement no. 1 supplements the prospectus dated April 4, 2022, as supplemented from time to time (the ?Prospectu
April 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 ny20002766x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of
April 21, 2022	SC 13G/A	RBOT / Vicarious Surgical Inc - Class A / SUN HUNG KAI & CO LTD - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Vicarious Surgical Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 9256
April 21, 2022	EX-99	JOINT FILING AGREEMENT CUSIP No. 92561V109 Schedule 13G Page 1 of 1 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and acc
April 6, 2022	424B3	VICARIOUS SURGICAL INC. Up to 122,932,036 Shares of Class A Common Stock Up to 19,789,860 Shares of Class B Common Stock Up to 10,400,000 Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-260281 PROSPECTUS VICARIOUS SURGICAL INC. Up to 122,932,036 Shares of Class A Common Stock Up to 19,789,860 Shares of Class B Common Stock Up to 10,400,000 Warrants This prospectus relates to the resale from time to time by the Selling Securityholders named in this prospectus (the ?Selling Securityholders?) of up to (i) 10,400,000 Private Place
March 31, 2022	POS AM	As filed with the U.S. Securities and Exchange Commission on March 31, 2022 As filed with the U.S. Securities and Exchange Commission on March 31, 2022 Registration No. 333-260281 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vicarious Surgical Inc. (Exact name of registrant as specified in its charter) Delaware 3842 87-2678169 (State or other juris
March 31, 2022	EX-10.10	Vicarious Surgical Inc. 2021 Equity Incentive Plan, and forms of agreement thereunder, as amended. Exhibit 10.10 VICARIOUS SURGICAL INC. 2021 EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Vicarious Surgical Inc. 2021 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the t
March 31, 2022	EX-4.1	Description of Securities Exhibit 4.1 DESCRIPTION OF The registrant?s SECURITIES The following summary of the material terms of the capital stock of Vicarious Surgical (formerly D8 Holdings Corp.) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Certificate of Incorporation (the ?Charter?), our Amended and Restated Bylaws (the ?Bylaws?) and the
March 31, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39384 VICARIOUS SURGICAL INC. (E
March 31, 2022	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num
March 23, 2022	EX-99	Joint Filing Agreement. CUSIP No. 92561V109 Schedule 13G Page 1 of 1 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and acc
March 23, 2022	SC 13G/A	RBOT / Vicarious Surgical Inc - Class A / SUN HUNG KAI & CO LTD - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Vicarious Surgical Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 9256
March 8, 2022	EX-99.1	VICARIOUS SURGICAL INVESTOR PRESENTATION MARCH 2022 INVESTOR PRESENTATION MARCH 2022 VICARIOUS SURGICAL INVESTOR PRESENTATION MARCH 2022 2 0 0 \| SUMMA R Y DISCLAIMER This presentation contains forward - looking statements. All statements other than s Exhibit 99.1 VICARIOUS SURGICAL INVESTOR PRESENTATION MARCH 2022 INVESTOR PRESENTATION MARCH 2022 VICARIOUS SURGICAL INVESTOR PRESENTATION MARCH 2022 2 0 0 \| SUMMA R Y DISCLAIMER This presentation contains forward - looking statements. All statements other than statements of historical facts contained herein are forward - looking statements reflecting the current beliefs and expectations of manage
March 8, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 VICARIOUS SURGICAL INC. Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 78 Fourth
March 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commission F
March 3, 2022	EX-99.1	Vicarious Surgical Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Vicarious Surgical Reports Fourth Quarter and Full Year 2021 Financial Results WALTHAM, Mass.- (BUSINESS WIRE) ? March 3, 2022 ? Vicarious Surgical Inc. (?Vicarious Surgical? or the ?Company?) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced its preli
February 17, 2022	EX-99	JOINT FILING AGREEMENT EX-99 CUSIP No. 92561V109 Schedule 13G Page 1 of 1 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness a
February 17, 2022	SC 13G	RBOT / Vicarious Surgical Inc - Class A / SUN HUNG KAI & CO LTD - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Vicarious Surgical Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 92561V109 (CUSIP Numb
February 14, 2022	SC 13G/A	RBOT / Vicarious Surgical Inc - Class A / Beryl Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vicarious Surgical Inc. (f/k/a D8 Holdings Corp.) (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 92561V109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropr
February 14, 2022	SC 13G/A	RBOT / Vicarious Surgical Inc - Class A / CITADEL ADVISORS LLC - VICARIOUS SURGICAL INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Vicarious Surgical Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (the ?Shares?) (Title of Class of Securities) 92
February 14, 2022	SC 13G/A	DEH / D8 Holdings Corp / GLAZER CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Vicarious Surgical Inc. formerly known as D8 Holdings Corp (Name of Issuer) Class A common stock, $0.0001 par value per share (Title of Class of Securities) G2614K110 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appro
February 11, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement is by and among Chelvey International Limited, E15 Fund II, LP, Shrikant Patnaik and Philip Angus Liang (collectively, the ?Filers?).
February 11, 2022	SC 13D/A	RBOT / Vicarious Surgical Inc - Class A / Chelvey International Ltd - AMENDMENT NO.1 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* VICARIOUS SURGICAL INC. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) Class A common stock: 92561V 109 (CUSIP Number) Adam Sachs c/o Vicarious Surgical Inc. 78 Fourth Avenue Waltham, Massachusetts 02451
February 8, 2022	SC 13G/A	DEH / D8 Holdings Corp / Polar Asset Management Partners Inc. - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vicarious Surgical Inc. (fka D8 Holdings Corp.) (Name of Issuer) Class A common stock, $0.0001 par value per share (Title of Class of Securities) G2614K110 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check t
December 17, 2021	S-8	As filed with the Securities and Exchange Commission on December 17, 2021 As filed with the Securities and Exchange Commission on December 17, 2021 Registration No.
December 2, 2021	S-8	As filed with the Securities and Exchange Commission on December 1, 2021 As filed with the Securities and Exchange Commission on December 1, 2021 Registration No.
November 8, 2021	424B3	VICARIOUS SURGICAL INC. Up to 124,141,216 Shares of Class A Common Stock Up to 19,789,860 Shares of Class B Common Stock Up to 10,400,000 Warrants PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(3) To Prospectus dated October 22, 2021 Registration No.
November 8, 2021	EX-99.1	Vicarious Surgical Reports Third Quarter 2021 Financial Results Exhibit 99.1 Vicarious Surgical Reports Third Quarter 2021 Financial Results WALTHAM, Mass.-(BUSINESS WIRE)- Vicarious Surgical Inc. (?Vicarious Surgical? or the ?Company?) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced third quarter 2021 financial results. ?This qu
November 8, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissio
November 8, 2021	EX-99.2	VICARIOUS SURGICAL INVESTOR PRESENTATION NOVEMBER 2021 INVESTOR PRESENTATION NOVEMBER 2021 VICARIOUS SURGICAL INVESTOR PRESENTATION NOVEMBER 2021 2 00 \| SUMMARY DISCLAIMER This presentation contains forward - looking statements. All statements other Exhibit 99.2 VICARIOUS SURGICAL INVESTOR PRESENTATION NOVEMBER 2021 INVESTOR PRESENTATION NOVEMBER 2021 VICARIOUS SURGICAL INVESTOR PRESENTATION NOVEMBER 2021 2 00 \| SUMMARY DISCLAIMER This presentation contains forward - looking statements. All statements other than statements of historical facts contained herein are forward - looking statements reflecting the current beliefs and expectations of
November 8, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICAR
October 25, 2021	424B3	VICARIOUS SURGICAL INC. Up to 124,141,216 Shares of Class A Common Stock Up to 19,789,860 Shares of Class B Common Stock Up to 10,400,000 Warrants PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-260281 VICARIOUS SURGICAL INC. Up to 124,141,216 Shares of Class A Common Stock Up to 19,789,860 Shares of Class B Common Stock Up to 10,400,000 Warrants This prospectus relates to the resale from time to time by the Selling Securityholders named in this prospectus (the ?Selling Securityholders?) of up to (i) 10,400,000 Private Place
October 21, 2021	CORRESP	VICARIOUS SURGICAL INC. 78 Fourth Avenue Waltham, Massachusetts 02451 CORRESP 1 filename1.htm VICARIOUS SURGICAL INC. 78 Fourth Avenue Waltham, Massachusetts 02451 October 21, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards RE: Vicarious Surgical Inc. Registration Statement on Form S-1 File No. 333-260281 Acceleration Request Dear Mr. Edwards: With respect t
October 20, 2021	EX-99.1	Vicarious Surgical Enters Long-Term Lease, Expanding Footprint for Continued Growth Exhibit 99.1 Vicarious Surgical Enters Long-Term Lease, Expanding Footprint for Continued Growth WALTHAM, Mass. - (BUSINESS WIRE) - October 20, 2021 ? Vicarious Surgical Inc. (?Vicarious Surgical? or the ?Company?) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced exec
October 20, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2021 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commissio
October 20, 2021	EX-10.2	Guaranty of Lease between Vicarious Surgical US Inc. and Fourth Avenue LLC dated as of October 14, 2021 Exhibit 10.2 GUARANTY Guaranty, dated as of October 14, 2021, by Vicarious Surgical Inc., a Delaware corporation with offices at 78 Fourth Avenue in Waltham, Massachusetts (?Guarantor?) to Fourth Avenue LLC, a Massachusetts limited liability company having offices at One Gateway Center, Newton, Massachusetts (?Landlord?). Fourth Avenue LLC is the landlord under a lease dated January 21, 2021 (as t
October 20, 2021	EX-10.1	Amendment to Lease, dated as of October 14, 2021, by and between Vicarious Surgical US Inc. and Fourth Avenue LLC Exhibit 10.1 AMENDMENT NUMBER one TO LEASE BETWEEN Fourth Avenue LLC AND Vicarious Surgical Inc. THIS AMENDMENT made this October 14, 2021 between Fourth Avenue LLC, a Massachusetts limited liability company having offices at One Gateway Center, Newton, Massachusetts (?Landlord?) and Vicarious Surgical US Inc. (fka Vicarious Surgical Inc.), a Delaware corporation, with offices in Waltham, Massachu
October 15, 2021	EX-21.1	List of Subsidiaries Exhibit 21.1 Subsidiaries of Registrant Name Percentage Ownership State or Country of Organization Vicarious Surgical US Inc. 100% Delaware
October 15, 2021	S-1	As filed with the U.S. Securities and Exchange Commission on October 15, 2021 As filed with the U.S. Securities and Exchange Commission on October 15, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vicarious Surgical Inc. (Exact name of registrant as specified in its charter) Delaware 3842 87-2678169 (State or other jurisdiction of incorporation or organizati
October 4, 2021	EX-2	Amended and Restated Registration Rights Agreement, dated as of September 17, 2021, by and among the Issuer, the Sponsor, certain affiliates of the Sponsor and certain holders of Legacy Vicarious securities (incorporated by reference from Exhibit 10.11 of the Form 8-K of the Issuer filed with the Securities and Exchange Commission on September 23, 2021 (File No. 001-39384)). Exhibit 2 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 17, 2021, is made and entered into by and among D8 Holdings Corp.
October 4, 2021	SC 13D	DEH / D8 Holdings Corp / Chelvey International Ltd - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* VICARIOUS SURGICAL INC. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) Class A common stock: 92561V 109 (CUSIP Number) Adam Sachs c/o Vicarious Surgical Inc. 78 Fourth Avenue Waltham, Massachusetts 02451
October 4, 2021	EX-1	Joint Filing Agreement, by and among Chelvey International Limited, E15 Fund II, LP, Shrikant Patnaik and Philip Angus Liang, dated as of September 27, 2021. Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement is by and among Chelvey International Limited, E15 Fund II, LP, Shrikant Patnaik and Philip Angus Liang (collectively, the ?Filers?).
September 30, 2021	SC 13D	DEH / D8 Holdings Corp / Sachs Adam - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* VICARIOUS SURGICAL INC. (Name of Issuer) Class B common stock, par value $0.0001 per share (Title of Class of Securities) Class B common stock: Not Applicable (CUSIP Number) Adam Sachs c/o Vicarious Surgical Inc. 78 Fourth Avenue Waltham, Massachusetts 02
September 30, 2021	SC 13G	DEH / D8 Holdings Corp / Greene Barry Stuart - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. )* VICARIOUS SURGICAL INC. (Name of Issuer) Class A common stock, par value $0.0001 per share Class B common stock, par value $0.0001 per share (Title of Clas
September 30, 2021	EX-1	Amended and Restated Registration Rights Agreement, dated as of September 17, 2021, by and among the Issuer, the Sponsor, certain affiliates of the Sponsor and certain holders of Legacy Vicarious securities (incorporated by reference from Exhibit 10.11 of the Form 8-K of the Issuer filed with the Securities and Exchange Commission on September 23, 2021 (File No. 001-39384)). EX-1 2 ea148007ex1vicarious.htm AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT, DATED AS OF SEPTEMBER 17, 2021, BY AND AMONG THE ISSUER, THE SPONSOR, CERTAIN AFFILIATES OF THE SPONSOR AND CERTAIN HOLDERS OF LEGACY VICARIOUS SECURITIES Exhibit 1 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 17
September 28, 2021	EX-2	Amended and Restated Registration Rights Agreement, dated as of September 17, 2021, by and among the Issuer, the Sponsor, certain affiliates of the Sponsor and certain holders of Legacy Vicarious securities (incorporated by reference from Exhibit 10.11 of the Form 8-K of the Issuer filed with the Securities and Exchange Commission on September 23, 2021 (File No. 001-39384)). EX-2 3 ea148005ex2vicariou.htm AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT, DATED AS OF SEPTEMBER 17, 2021, BY AND AMONG THE ISSUER, THE SPONSOR, CERTAIN AFFILIATES OF THE SPONSOR AND CERTAIN HOLDERS OF LEGACY VICARIOUS SECURITIES Exhibit 2 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 17,
September 28, 2021	SC 13D	DEH / D8 Holdings Corp / Innovation Endeavors III LP - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* VICARIOUS SURGICAL INC. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) Class A common stock: 92561V 109 (CUSIP Number) Adam Sachs c/o Vicarious Surgical Inc. 78 Fourth Avenue Waltham, Massachusetts 02451
September 28, 2021	SC 13D	DEH / D8 Holdings Corp / Khalifa Sammy - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* VICARIOUS SURGICAL INC. (Name of Issuer) Class B common stock, par value $0.0001 per share (Title of Class of Securities) Class B common stock: Not Applicable (CUSIP Number) Adam Sachs c/o Vicarious Surgical Inc. 78 Fourth Avenue Waltham, Massachusetts 02
September 28, 2021	EX-1	Joint Filing Agreement, by and between Dror Berman and Innovation Endeavors III LP, dated as of September 27, 2021. Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement is by and between Dror Berman and Innovation Endeavors III LP (collectively, the ?Filers?).
September 28, 2021	EX-1	Amended and Restated Registration Rights Agreement, dated as of September 17, 2021, by and among the Issuer, the Sponsor, certain affiliates of the Sponsor and certain holders of Legacy Vicarious securities (incorporated by reference from Exhibit 10.11 of the Form 8-K of the Issuer filed with the Securities and Exchange Commission on September 23, 2021 (File No. 001-39384)). Exhibit 1 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of September 17, 2021, is made and entered into by and among D8 Holdings Corp.
September 27, 2021	SC 13D	DEH / D8 Holdings Corp / Khosla Ventures V, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Vicarious Surgical Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 92561V109 (CUSIP Number) John Demeter Khosla Ventures 2128 Sand Hill Road Menlo Park, California 94025 (650) 376-8500 (Name, Address
September 27, 2021	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. Dated: September 27, 2021 KHOSLA VENTURES SE
September 24, 2021	SC 13G	DEH / D8 Holdings Corp / Gates Ventures, Llc - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vicarious Surgical Inc. (Name of Issuer) Class A common Stock, $0.0001 par value (Title of Class of Securities) 92561V109 (CUSIP Number) September 17, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
September 23, 2021	EX-10.13	Director Nomination Agreement, dated as of September 17, 2021, by and between Vicarious Surgical Inc. (formerly D8 Holdings Corp.) and D8 Sponsor LLC. Exhibit 10.13 DIRECTOR NOMINATION AGREEMENT THIS DIRECTOR NOMINATION AGREEMENT (the ?Agreement?) is made and entered into as of September 17, 2021 (the ?Effective Time?), by and among Vicarious Surgical Inc., a Delaware corporation (f/k/a D8 Holdings Corp.) (the ?Company?), and D8 Sponsor LLC, a Cayman Islands limited liability company (the ?Sponsor?). Capitalized terms used but not otherwise defi
September 23, 2021	EX-3.2	Amended and Restated Bylaws of Vicarious Surgical Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF VICARIOUS SURGICAL INC. (the ?Corporation?) * * * * * Article 1 Offices Section 1.01. Registered Office. The address of the registered office of the Corporation in the State of Delaware, and the name of the Corporation?s registered agent at such address, shall be as set forth in the Corporation?s certificate of incorporation, as the same may be amended an
September 23, 2021	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Change in Shell Company Status, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2021 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of incorporation) (Commiss
September 23, 2021	EX-10.11	Amended and Restated Registration Rights Agreement, dated as of September 17, 2021, by and among Vicarious Surgical Inc. (formerly D8 Holdings Corp.), Vicarious Surgical Operating Co. (formerly Vicarious Surgical Inc.) and certain of their securityholders. Exhibit 10.11 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of September 17, 2021, is made and entered into by and among D8 Holdings Corp., a Cayman Islands exempted company (the ?Company?), D8 Sponsor LLC, a Cayman Islands limited liability company (the ?Sponsor?), the undersigned parties listed under ?Spons
September 23, 2021	EX-10.12	Form of Indemnification Agreement. Exhibit 10.12 Indemnification Agreement This Indemnification Agreement (this ?Agreement?) is made and entered into this day of , 20, by and between Vicarious Surgical Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). Recitals Whereas, qualified persons are reluctant to serve corporations as directors, officers or otherwise unless they are provided with broad indemnification and ins
September 23, 2021	EX-16.1	Letter from WithumSmith+Brown, PC to the SEC, dated September 23, 2021. Exhibit 16.1 September 23, 2021 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 United States of America Commissioners: We have read the statements of Vicarious Surgical Inc. (formally known as D8 Holdings Corp.) included under Item 4.01 of its Form 8-K dated September 17, 2021. We agree with the statements concerning our Firm under Item 4.01
September 23, 2021	EX-99.4	UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Exhibit 99.4 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K (the ?Form 8-K?) filed with the Securities and Exchange Commission (the ?SEC?) on September 17, 2021. Unless the context otherwise requires, the ?Combined Company? refers to Vicarious Surgical Inc.(f/k/a D8 Hold
September 23, 2021	EX-21.1	List of Subsidiaries. EX-21.1 11 ea147795ex21-1vicarious.htm LIST OF SUBSIDIARIES Exhibit 21.1 Subsidiaries of Registrant Name Percentage Ownership State or Country of Organization Vicarious Surgical Operating Co. 100% Delaware
September 23, 2021	EX-99.3	RISK FACTORS Exhibit 99.3 RISK FACTORS Except for the historical information contained herein, this report contains forward-looking statements that involve risks and uncertainties. These statements include projections about our finances, plans and objectives for the future, future operating and economic performance and other statements regarding future performance. These statements are not guarantees of future
September 23, 2021	EX-99.1	VICARIOUS SURGICAL INC. UNAUDITED CONDENSED BALANCE SHEETS (in thousands, except share and per share data) Exhibit 99.1 VICARIOUS SURGICAL INC. UNAUDITED CONDENSED BALANCE SHEETS (in thousands, except share and per share data) June 30, December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $ 7,706 $ 16,867 Prepaid expenses and other current assets 495 258 Total current assets 8,201 17,125 Restricted cash 622 118 Property and equipment, net 1,520 445 Deferred transaction costs 1,774 ? O
September 23, 2021	EX-4.1	Specimen Class A Common Stock Certificate Exhibit 4.1
September 23, 2021	EX-10.9	Vicarious Surgical Inc. 2014 Stock Incentive Plan, as amended. Exhibit 10.9 Amended and Restated 2014 Stock Incentive Plan of Vicarious Surgical Inc. i Table of Contents Page 1. Purpose 1 2. Eligibility 1 3. Administration and Delegation 1 (a) Administration by the Board 1 (b) Appointment of Committees 2 4. Stock Available for Awards 2 (a) Number of Shares 2 (b) Substitute Awards 2 5. Stock Options 2 (a) General 2 (b) Incentive Stock Options 2 (c) Exercise Pr
September 23, 2021	EX-10.10	Vicarious Surgical Inc. 2021 Equity Incentive Plan, and forms of agreement thereunder. Exhibit 10.10 VICARIOUS SURGICAL INC. 2021 EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Vicarious Surgical Inc. 2021 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the t
September 23, 2021	8-K/A	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2021 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39384 87-2678169 (State or other jurisdiction of inc
September 23, 2021	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of the financial condition and results of operations of Vicarious Surgical Inc. (for purposes of this section, ?Vicarious Surgical?) should be read together with Vicarious Surgical?s audited financial statements as of and for the years ended December 31, 2020 and
September 23, 2021	EX-3.1	Certificate of Incorporation of Vicarious Surgical Inc. Exhibit 3.1 CERTIFICATE OF INCORPORATION OF VICARIOUS SURGICAL INC. Pursuant to the General Corporation Law of the State of Delaware ARTICLE 1. NAME The name of the corporation is Vicarious Surgical Inc. ARTICLE 2. REGISTERED OFFICE AND AGENT The address of its registered office in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, DE 19801. The name of its registered a
September 20, 2021	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on October 01, 2021, pursuant to the provisions of Rule 12d2-2 (a).
September 16, 2021	425	Vicarious Surgical Business Combination Approved; Stock to Begin Trading on the New York Stock Exchange as “RBOT” Filed by D8 Holdings Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: D8 Holdings Corp. Commission File Nos. 333-257055 and 333-259559 Date: September 16, 2021 Set forth below is a press release issued by D8 Holdings Corp. and Vicarious Surgical Inc. on September 15, 2021 announcing the r
September 15, 2021	EX-99.1	Vicarious Surgical Business Combination Approved; Stock to Begin Trading on the New York Stock Exchange as “RBOT” Exhibit 99.1 Vicarious Surgical Business Combination Approved; Stock to Begin Trading on the New York Stock Exchange as ?RBOT? ? Vicarious Surgical to debut on NYSE as a disruptive next-generation surgical robotics company ? $220 million in gross cash proceeds to catalyze advancement of Vicarious Surgical?s robotic technology, clinical programs, and strategic business initiatives ? Combined compan
September 15, 2021	S-4MEF	As filed with the Securities and Exchange Commission on September 15, 2021 As filed with the Securities and Exchange Commission on September 15, 2021 Registration No.
September 15, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2021 D8 Holdings Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-39384 N/A (State or other jurisdiction of incorporation) (Commission Fil
September 14, 2021	425	2 Filed by D8 Holdings Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: D8 Holdings Corp. Commission File No. 333-257055 Date: September 13, 2021 On September 12, 2021, Adam Sachs, the Co-founder and Chief Executive Officer of Vicarious Surgical Inc., David Styka, the Executive Chairman of
September 14, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 14, 2021 D8 HOLDINGS CORP. (Exact name of registrant as specified in its charter) Cayman Islands 001-39384 N/A (State or other jurisdiction of incorporation) (Commission Fil
September 14, 2021	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 14, 2021 D8 HOLDINGS CO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 14, 2021 D8 HOLDINGS CORP. (Exact name of registrant as specified in its charter) Cayman Islands 001-39384 N/A (State or other jurisdiction of incorporation) (Commission Fil
September 10, 2021	EX-99.1	Vicarious Surgical Inc. and D8 Holdings Corp. Announce Additional PIPE Commitments Exhibit 99.1 Vicarious Surgical Inc. and D8 Holdings Corp. Announce Additional PIPE Commitments WALTHAM, Mass., & HONG KONG, September 9, 2021 - (BUSINESS WIRE) - Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”), a next-generation robotics technology company seeking to improve both cost and efficiency of surgical procedures as well as patient outcomes, and D8 Holdings Corp. (“D8”) (
September 10, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 9, 2021 D8 HOLDINGS CORP. (Exact name of registrant as specified in its charter) Cayman Islands 001-39384 N/A (State or other jurisdiction of incorporation) (Commission File
September 10, 2021	425	Vicarious Surgical Inc. and D8 Holdings Corp. Announce Additional PIPE Commitments Filed by D8 Holdings Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: D8 Holdings Corp. Commission File No. 333-257055 Date: September 10, 2021 The press release set forth below was furnished by D8 Holdings Corp. on September 10, 2021 as Exhibit 99.1 to a Current Report on Form 8-K in con
September 10, 2021	425	2 425 1 ea147204-425d8holdings.htm FORM 425 Filed by D8 Holdings Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: D8 Holdings Corp. Commission File No. 333-257055 Date: September 10, 2021 The following communications were made available by Vicarious Surgical Inc. (“Vicarious Surgical”) on L
September 7, 2021	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 6, 2021 D8 HOLDINGS COR Filed by D8 Holdings Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: D8 Holdings Corp. Commission File No. 333-257055 Date: September 7, 2021 Set forth below is a Current Report on Form 8-K filed by D8 Holdings Corp. on September 7, 2021 in connection with the proposed business combinati
September 7, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 6, 2021 D8 HOLDINGS CORP. (Exact name of registrant as specified in its charter) Cayman Islands 001-39384 N/A (State or other jurisdiction of incorporation) (Commission File
August 27, 2021	425	Filed by D8 Holdings Corp. 425 1 ea146596-425d8holdings.htm FORM 425 Filed by D8 Holdings Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: D8 Holdings Corp. Commission File No. 333-257055 Date: August 27, 2021 On August 28, 2021, D8 Holdings Corp. and Vicarious Surgical Inc. made available the updated investor pres
August 26, 2021	EX-10.2	Promissory Note, dated August 23, 2021, issued by D8 Holdings Corp. to Cadin Limited. Exhibit 10.2 THIS CONVERTIBLE PROMISSORY NOTE (THIS ?NOTE?) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFER
August 26, 2021	8-K/A	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2021 D8 Holdings Corp. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-39384 N/A (State or Other Jurisdiction of Incorporation) (C
August 26, 2021	EX-10.1	Promissory Note, dated August 23, 2021, issued by D8 Holdings Corp. to Bright Insight Holdings Limited. Exhibit 10.1 THIS CONVERTIBLE PROMISSORY NOTE (THIS ?NOTE?) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFER
August 24, 2021	EX-10.2	Promissory Note, dated August 23, 2021, issued by D8 Holdings Corp. to Cadin Limited. Exhibit 10.2 THIS CONVERTIBLE PROMISSORY NOTE (THIS ?NOTE?) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFER
August 24, 2021	EX-10.1	Promissory Note, dated August 23, 2021, issued by D8 Holdings Corp. to Bright Insight Holdings Limited. Exhibit 10.1 THIS CONVERTIBLE PROMISSORY NOTE (THIS ?NOTE?) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFER
August 24, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2021 D8 Holdings Corp. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-39384 N/A (State or Other Jurisdiction of Incorporation) (Commission File Numbe
August 24, 2021	425	Filed by D8 Holdings Corp. Filed by D8 Holdings Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: D8 Holdings Corp. Commission File No. 333-257055 Date: August 24, 2021 On August 18, 2021, Adam Sachs, the Co-founder and Chief Executive Officer of Vicarious Surgical Inc., participated in an interview with Randi Zucke
August 23, 2021	SC 13G	DEH / D8 Holdings Corp / Beryl Capital Management LLC Passive Investment SC 13G 1 d8holdings13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* D8 Holdings Corp. (Name of Issuer) Class A Ordinary Shares, par value $0.0001 (Title of Class of Securities) G2614K110 (CUSIP Number) August 13, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate
August 17, 2021	425	1 425 1 ea146033-425d8holdingscorp.htm FORM 425 Filed by D8 Holdings Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: D8 Holdings Corp. Commission File No. 333-257055 Date: August 17, 2021 On August 12, 2021, Adam Sachs, the Co-founder and Chief Executive Officer of Vicarious Surgical Inc.,
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to D8 HOLDINGS CORP. (Exact name of registrant
August 12, 2021	424B3	Filed pursuant to Rule 424(b)(3) Filed pursuant to Rule 424(b)(3) Registration No. 333-257055 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING OF D8 HOLDINGS CORP. (A CAYMAN ISLANDS EXEMPTED COMPANY) PROSPECTUS FOR 110,769,991 SHARES OF CLASS A COMMON STOCK, 19,726,836 SHARES OF CLASS B COMMON STOCK AND 26,150,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK OF D8 HOLDINGS CORP. (TO BE RENAMED ?VICARIOUS SURGICAL INC.? FO
August 12, 2021	425	1 Filed by D8 Holdings Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: D8 Holdings Corp. Commission File No. 333-257055 Date: August 12, 2021 On August 11, 2021, Adam Sachs, the Co-founder and Chief Executive Officer of Vicarious Surgical Inc., participated in an interview on Health Profes
August 6, 2021	CORRESP	D8 Holdings Corp. Unit 1008, 10/F, Champion Tower 3 Garden Road Central, Hong Kong CORRESP 1 filename1.htm D8 Holdings Corp. Unit 1008, 10/F, Champion Tower 3 Garden Road Central, Hong Kong August 6, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, D.C. 20549 Re: D8 Holdings Corp. Amendment No. 2 to Registration Statement on Form S-4 Filed August 2, 2021 File No. 333-257055 Ladies
August 3, 2021	425	Filed by D8 Holdings Corp. Filed by D8 Holdings Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: D8 Holdings Corp. Commission File No. 333-257055 Date: August 3, 2021 On June 25, 2021, Adam Sachs, the Co-founder and Chief Executive Officer of Vicarious Surgical Inc., participated in an interview at the Life Science
August 2, 2021	EX-4.2	Specimen Class B Common Stock Certificate of New Vicarious Surgical. Exhibit 4.2 NUMBER SHARES C VICARIOUS SURGICAL INC. INCORPORATED UNDER THE LAWS OF DELAWARE CLASS B COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS This Certifies that CUSIP is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF CLASS B COMMON STOCK OF THE PAR VALUE OF $0.0001 EACH OF VICARIOUS SURGICAL INC. transferable on the books of the Company in person or by duly authorized attorney upon s
August 2, 2021	EX-2.2	Plan of Domestication. Exhibit 2.2 PLAN OF DOMESTICATION This PLAN OF DOMESTICATION (the ?Plan of Domestication?) is made on [?], 2021 and sets forth the terms and conditions pursuant to which D8 Holdings Corp., a Cayman Islands exempted company (?D8?), shall effect a domestication into a Delaware corporation (the ?Domestication?) to be known as Vicarious Surgical Inc., pursuant to Sections 265 and 388 of the Delaware G
August 2, 2021	EX-99.1	Form of Preliminary Proxy Card. Exhibit 99.1
August 2, 2021	EX-4.1	Specimen Class A Common Stock Certificate of New Vicarious Surgical. Exhibit 4.1 NUMBER SHARES C VICARIOUS SURGICAL INC. INCORPORATED UNDER THE LAWS OF DELAWARE CLASS A COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS This Certifies that CUSIP is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF CLASS A COMMON STOCK OF THE PAR VALUE OF $0.0001 EACH OF VICARIOUS SURGICAL INC. transferable on the books of the Company in person or by duly authorized attorney upon s
August 2, 2021	EX-3.4	Certificate of Domestication. Exhibit 3.4 STATE OF DELAWARE CERTIFICATE OF DOMESTICATION FROM A NON-DELAWARE CORPORATION TO A DELAWARE CORPORATION PURSUANT TO SECTION 388 OF THE DELAWARE GENERAL CORPORATION LAW D8 Holdings Corp., presently a Cayman Islands exempted company, organized and existing under the laws of the Cayman Islands (the ?Non-Delaware Corporation?), does hereby certify: 1) The Non-Delaware Corporation was firs

RBOT.WS / Vicarious Surgical Inc. - Equity Warrant - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)